Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The study comparing the incidence of cardiovascular events between high-dose ARB [angiotensin II receptor antagonists] monotherapy and combination therapy with ARB and calcium channel blocker in Japanese elderly hypertensive patients at high cardiovascular risk.

Trial Profile

The study comparing the incidence of cardiovascular events between high-dose ARB [angiotensin II receptor antagonists] monotherapy and combination therapy with ARB and calcium channel blocker in Japanese elderly hypertensive patients at high cardiovascular risk.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jan 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Amlodipine; Azelnidipine; Calcium channel antagonists
  • Indications Cardiovascular disorders; Hypertension
  • Focus Therapeutic Use
  • Acronyms OSCAR
  • Most Recent Events

    • 05 Apr 2011 Results presented as a late-breaking abstract at the 60th Annual Scientific Session of the American College of Cardiology.
    • 04 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jul 2007 Status changed from recruiting to in progress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top